Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy
2019 Value Health
Drummond, M. F. | Neumann, P. J. | Sullivan, S. D. | Fricke, F. U. | Tunis, S. | Dabbous, O. | Toumi, M. |
Cost-Benefit Analysis, *Decision Making, Genetic Therapy/*economics/trends, Humans, Quality-Adjusted Life Years, *cost-effectiveness analysis, *drug pricing, *reimbursement, *specialty drugs,
The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in Health and Medicine, has been used to specify the required methodological features of economic evaluations of healthcare interventions. In the case of gene therapy, there is a difference of opinion on whether a specific methodological reference case is required. The aim of this article was to provide a more detailed analysis of the characteristics of gene therapy and the extent to which these characteristics warrant modifications to the methods suggested in general reference cases for economic evaluation. We argue that a completely new reference case is not required, but propose a tailored checklist that can be used by analysts and decision makers to determine which aspects of economic evaluation should be considered further, given the unique nature of gene therapy.